OneSource Specialty Pharma has received regulatory approval in Saudi Arabia to commercialise a generic version of Ozempic® (semaglutide) in collaboration with Hikma Pharmaceuticals.

• Regulatory Approval: The Saudi Food and Drug Authority has authorised the generic semaglutide for commercialisation.
• Partnership: OneSource and Hikma will collaborate to bring the therapy to the Saudi market.
• Market Context: The approval enables availability of a generic GLP-1 therapy in Saudi Arabia.

This summary is based on a report from BioSpectrum Asia.